JAK1 Inhibitor From Galapagos Headed To Phase III – With Or Without AbbVie
This article was originally published in The Pink Sheet Daily
Executive Summary
Filgotinib posts promising interim Phase IIb results in rheumatoid arthritis; although more results are to come. AbbVie seems likely to opt in later this year on the potential successor to Humira.
You may also be interested in...
After The Anti-TNFs, What’s Next In Autoimmune Disease?
With the threat of biosimilars looming closer, the leaders in autoimmune disease are scrambling to bring novel drugs to market and extend their dominance beyond the anti-TNF class. But toppling the anti-TNFs’ reign won’t be easy, especially if cheaper biosimilar copies reach the market.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.